{"id":105677,"date":"2026-03-05T10:20:08","date_gmt":"2026-03-05T10:20:08","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/priavoid-to-present-initial-phase-2-safety-data-for-alzheimers-and-preclinical-poc-for-parkinsons-programs-at-ad-pd-2026\/"},"modified":"2026-03-05T10:20:08","modified_gmt":"2026-03-05T10:20:08","slug":"priavoid-to-present-initial-phase-2-safety-data-for-alzheimers-and-preclinical-poc-for-parkinsons-programs-at-ad-pd-2026","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/priavoid-to-present-initial-phase-2-safety-data-for-alzheimers-and-preclinical-poc-for-parkinsons-programs-at-ad-pd-2026\/","title":{"rendered":"Priavoid to Present Initial Phase 2 Safety Data for Alzheimer\u2018s and Preclinical PoC for Parkinson\u2018s Programs at AD\/PD\u2122 2026"},"content":{"rendered":"
\n

Dusseldorf, Germany, March 5, 2026 –\u00a0<\/b>Priavoid GmbH<\/a> (\u201cPriavoid\u201d) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085<\/a>) evaluating its lead candidate PRI-002 in Alzheimer\u2019s disease (AD), as well as preclinical proof-of-concept data for its candidate PRI-101 in alpha-synucleinopathy models like Parkinson\u2019s disease (PD) at the upcoming\u00a0AD\/PD\u2122 2026 International Conference, taking place from March 17-21, 2026 in Copenhagen, Denmark. Both candidates are based on Priavoid\u2019s proprietary development platform and represent a novel class of orally available all-d-peptide therapeutics designed to detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. <\/p>\n

Initial Phase 2 safety data for PRI-002, which targets amyloid-beta (A\u03b2) oligomers, will be outlined in an oral presentation by Priavoid\u2019s Chief Science Officer, Prof. Dr. Dieter Willbold. The results indicate a favorable safety and tolerability profile, particularly regarding Amyloid-Related Imaging Abnormalities (ARIA). Following review of relevant safety data, the Drug Safety and Monitoring Board (DSMB) recommended continuing the trial without further ARIA monitoring. <\/p>\n

The preclinical proof-of-concept data for PRI-101, a candidate designed to target alpha-synuclein (\u03b1-syn) aggregates, will be shared as a poster presentation and include encouraging efficacy data in several in vitro<\/i> and in vivo<\/i> PD models. <\/p>\n

Priavoid will also present additional posters, including updates from its discovery-stage programs aimed at addressing tauopathies and amyotrophic lateral sclerosis (ALS). <\/p>\n

Details of the Talk and Poster Sessions:<\/u><\/b><\/p>\n

Oral Presentation:<\/u><\/b><\/p>\n

Abstract Title:<\/b> The Abeta Oligomer Disassembling Compound PRI-002 Does Not Cause ARIA in an Ongoing Phase 2 Trial (ID 2426)
Presenting author: <\/b>Prof. Dr. Dieter Willbold, Priavoid GmbH
Session:<\/b> 4760 – The App Pathway: From Hidden Fragments to Therapeutic Targets in AD
Date & Time:<\/b> March 17, 2026, at 3:30 pm CET \/ 9:30 am EST <\/p>\n

Poster:<\/u><\/b><\/p>\n

Abstract Title:<\/b> #514: Disassembly of \u03b1-Synuclein Aggregates by the All-d-Peptide PRI-101: Preclinical Efficacy In Vitro <\/i>and In Vivo<\/i>
Presenting author: <\/b>Dr. Marc Sevenich, Priavoid GmbH
Date & <\/b>Time:<\/b> March 19, 2026, 1:50 pm CET until March 21, 2026, 5 pm CET
Poster board number:<\/b> SHIFT 02-152<\/p>\n

Details for additional poster presentations at AD\/PD 2026 can be found here<\/a>. <\/p>\n

The PRImus-AD trial is funded by PRInnovation GmbH, affiliate to The Federal Agency for Breakthrough Innovation \u2013 SPRIND GmbH<\/a>.<\/p>\n

About Priavoid<\/b>
Priavoid\u2019s novel class of orally available all-d-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer\u2019s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients. <\/p>\n

Contacts:<\/b><\/p>\n

Priavoid GmbH<\/b>
Email: media@priavoid.com<\/a> <\/p>\n

Media Requests<\/b>
Trophic Communications
Anja Heuer and Marie Weickert, PhD
Phone: +49 151 106 199 05 \u00a0
Email: priavoid@trophic.eu<\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Dusseldorf, Germany, March 5, 2026 –\u00a0Priavoid GmbH (\u201cPriavoid\u201d) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its lead candidate PRI-002 in Alzheimer\u2019s disease (AD), as well as preclinical proof-of-concept data for its candidate PRI-101 in alpha-synucleinopathy models like Parkinson\u2019s disease (PD) at the upcoming\u00a0AD\/PD\u2122 2026 […]<\/p>\n","protected":false},"author":2,"featured_media":105678,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1a8f9247-bae4-4ea2-94d2-68e3be4b56b0","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-105677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t